After FDA approval in the US markets, one would think that if they are able to sign these contracts, all the necessary DD they have prior to the FDA approval would be paying off in ramping up in penetrating these markets given they have already integrated with PCC which has 50% of the market for beds.
While it is just speculation, would think they either they raise a large amount AFTER fda approval, as entering a new international market requires a large amount of cash to scale up quickly or go the route of signing large monetary licences that with significantly increase their ARR and turn CFP.
They do have the first mover advantage for about another decade so am not too worried with competition, but would obviously love less dilution.
Add to My Watchlist
What is My Watchlist?
